BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Assembly Biosciences (ASMB)Assembly BiosciencesFinancing

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an

Open original release

Related news

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ASMBAssembly Biosciences2025-08-08 12:05 EST

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

OGENOragenics2025-07-01 12:31 EST

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

OGENOragenics2025-07-02 20:15 EST

Oragenics Completes Approximately $16.5 Million Offering

ANTXAN2 Therapeutics2026-03-09 11:00 EST

AN2 Therapeutics Announces $40 Million Private Placement Financing

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

VIRIVirios Therapeutics2026-01-12 13:30 EST

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

SPROSpero Therapeutics2023-11-01 08:05 EST

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

SCYXSCYNEXIS2026-03-31 10:45 EST

SCYNEXIS Announces $40.0 Million Private Placement

VIRIVirios Therapeutics2025-11-11 13:45 EST

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

View all latest news

Assembly Biosciences

Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery. Its story is built around trying to translate targeted biology into therapies for difficult infectious diseases.

Recent company news

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

ASMBAssembly Biosciences2026-05-13 06:00 EST

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Stock data

Close
25.91 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States